One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

Alimentary Pharmacology and Therapeutics

Volumn 46, Issue 3, 2017, Pages 310-321

  Amiot, Aurelien ^a   Serrero, Melanie ^a   Peyrin Biroulet, Laurent ^a   Filippi, Jerome ^a   Pariente, Benjamin ^a   Roblin, Xavier ^a   Buisson, Anthony ^a   Stefanescu, Carmen ^a   Trang Poisson, Caroline ^a   Altwegg, Romain ^a   Marteau, Philippe ^a   Vaysse, Thibaud ^a   Bourrier, Anne ^a   Nancey, Stephane ^a   Laharie, David ^a   Allez, Matthieu ^a   Savoye, Guillaume ^a   Moreau, Jacques ^a   Vuitton, Lucine ^a   Viennot, Stephanie ^a   Aubourg, Alexandre ^a   Pelletier, Anne Laure ^a   Bouguen, Guillaume ^a   Abitbol, Vered ^a   Gagniere, Charlotte ^a   Bouhnik, Yoram ^a   Grimaud, Jean Charles ^a   Zallot, Camille ^a   Bigard, Marc Andre ^a   Hebuterne, Xavier ^a   Nachury, Maria ^a   Desreumaux, Pierre ^a   del Tedesco, Emilie ^a   Bommelaer, Gilles ^a   Boureille, Arnaud ^a   Dray, Xavier ^a   Carbonnel, Franck ^a   Seksik, Philippe ^a   Beaugerie, Laurent ^a   Cosnes, Jacques ^a   Sokol, Harry ^a   Landman, Cecilia ^a   Boschetti, Gilles ^a   Poullenot, Florian ^a   Gornet, Jean Marc ^a   Baudry, Clautilde ^a   Koch, Stephane ^a   Picon, Laurence ^a   Sickersen, Gaelle ^a   Chaussade, Stanislas ^a   Nahon, Stephane ^a   Winkfield, Betsy ^a   Brixi benmansour, Hedia ^a   Gincul, Rodica ^a   Barberis, Jean Christophe ^a   Bonaz, Bruno ^a   Michiels, Christophe ^a   Zerbib, Franck ^a   de Beauregard, Marie Bourrier ^a   Locher, Christophe ^a   Davin Couve, Sophie ^a   Poirette, Armelle ^a   Guillem, Laurence ^a   Stetiu Mocanu, Monica ^a   Philippe, Beau ^a   Beorchia, Sylvain ^a   Al Qaddi, Jawad ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PURINE DERIVATIVE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTHRALGIA; ARTICLE; CAMPYLOBACTER ENTERITIS; CEREBROVASCULAR ACCIDENT; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; INFLUENZA; INFUSION RELATED REACTION; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PERIANAL ABSCESS; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RECTUM CARCINOMA; REMISSION; RHINOPHARYNGITIS; SINUSITIS; SKIN MANIFESTATION; SMALL INTESTINE PERFORATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MIDDLE AGED;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85020291356     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14167     Document Type: Article

References (20)

1. Fiorino G, Correale C, Fries W, Repici A, Malesci A, Danese S. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:567-572.
2. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579-594.
3. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
4. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
5. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(618–627):e3.
6. Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147:132-142 e4.
7. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324-1338.
8. Amiot A, Grimaud J-C, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14:1593-1601.
9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
10. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
11. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619-1635.
12. Shah SC, Colombel J-F, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1245-1255.
13. Loftus EV Jr, Colombel JF, Previtali A, Smyth M. Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitis. J Crohns Colitis. 2016;10:S58.
14. Vermeire S, Feagan BG, Mody R, Previtali A, Abhyankar B. Response and remission rates with up to 3 years of vedolizumab treatment in patients with Crohn's disease. J Crohns Colitis. 2016;13:S406.
15. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499-2507.
16. Pineton de Chambrun G, Peyrin-Biroulet C, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15-29.
17. Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S. Vedolizumab Germany Consortium Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090-1102.
18. Shelton E, Allegretti JR, Stevens B, et al. Efficacy of Vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21:2879-2885.
19. Amiot A, Peyrin-Biroulet L. Currrent, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther Adv Gastroenterol. 2015;8:66-82.
20. Colombel JF, Sands BE, Rutgeerts PJ, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66:839-851.